AI Article Synopsis
- The study aims to evaluate the effectiveness of Photon-Counting CT (PCCT) compared to Dual-Source CT (DSCT) in reducing radiation dosage while improving the quality of chest CT images.
- Tests were conducted on phantoms using both CT technologies at various dose levels, with parameters like noise magnitude and detectability of specific lung lesions assessed to measure performance.
- Results showed that PCCT had significantly lower noise levels and better detectability of lung lesions, with a potential dose reduction of nearly 59% compared to DSCT, indicating PCCT's promise for safer chest imaging in patients.
Article Abstract
Purpose: To compare potential dose reduction and quality improvement in chest CT images with Photon-Counting CT (PCCT) versus a Dual-Source CT (DSCT).
Methods: Acquisitions on phantoms were performed on a DSCT and a PCCT at 5 dose levels (9.5/7.5/6.0/2.5/0.4 mGy). Noise power spectrum (NPS) and task-based transfer function (TTF) were calculated to assess noise magnitude and noise texture (f) and spatial resolution (f), respectively. Computed detectability indexes (d') modelled the detection of 2 chest lesions: subsolid pulmonary nodules (SPN) and high-contrast pulmonary nodules (HCN). Two radiologists subjectively assessed the quality of chest images on an anthropomorphic phantom.
Results: For all dose levels, noise magnitude was significantly lower with PCCT than with DSCT (-44.7 ± 3.0 %; p < 0.05). Identical outcomes were found for noise texture (f; -6.2 ± 0.5 %; p < 0.05). f values were significantly higher with DSCT than with PCCT from 9.5 to 6 mGy for iodine insert (p < 0.05) and from 7.5 to 2.5 mGy for air insert (p < 0.05), but similar for both inserts at other dose levels. For all dose levels, d' values were significantly higher with PCCT than DSCT (71.9 ± 5.4 % for HCN and 65.6 ± 13.5 % for SPN). From 9.5 to 2.5 mGy, the potential dose reduction was -59.0 ± 3.9 % for both lesions with PCCT compared to DSCT. Chest images were rated satisfactory for clinical use by the radiologists with both CTs for all dose levels, except at 0.4 mGy.
Conclusion: Noise magnitude and detectability of chest lesions were better with PCCT than with the DSCT. PCCT may offer great potential for dose reduction in patients undergoing chest CT examinations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmp.2024.104844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bolanthus turcicus: a promising antidiabetic with in-vitro antioxidant, enzyme inhibitory and antiadipogenic activities.
J Mol Histol
December 2024
Complementary and Integrative Medicine, Department of Traditional, Ankara Yıldırım Beyazıt University, Ankara, Türkiye, Turkey.
It is crucial to investigate new anti-diabetic agents and therapeutic approaches targeting molecules in potential signaling pathways for the treatment of Type 2 diabetes mellitus (T2DM). The objective of the study was to investigate the total phenolic content, antioxidant capacity, α-glucosidase, and α-amylase inhibitory activities of Bolanthus turcicus (B. turcicus), as well as their cytotoxic, anti-adipogenic, anti-diabetic, apoptotic, and anti-migration potential on adipocytes.
View Article and Find Full Text PDFBiodistribution and dosimetry of the PET radioligand [F]CHDI-650 in mice for detection of mutant huntingtin aggregates.
EJNMMI Res
December 2024
μNEURO Research Centre of Excellence, Universiteitsplein 1, University of Antwerp, Antwerp, Belgium.
Background: Huntington's disease (HD) is a rare neurodegenerative disorder caused by an expansion of the CAG trinucleotide repeat in the huntingtin gene which encodes the mutant huntingtin protein (mHTT) that is associated with HD-related neuropathophysiology. Noninvasive visualization of mHTT aggregates in the brain, with positron emission tomography (PET), will allow to reliably evaluate the efficacy of therapeutic interventions in HD. This study aimed to assess the radiation burden of [F]CHDI-650, a novel fluorinated mHTT radioligand, in humans based on both in vivo and ex vivo biodistribution in mice and subsequent determination of dosimetry for dosing in humans.
View Article and Find Full Text PDFSynergistic Anxiolytic Effects of Linalool and Sesamol Co-Treatment on Swiss Albino Mice: A Potential GABAergic Intervention.
Synapse
January 2025
Department of Biochemistry & Molecular Biology, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh.
Sesamol (SES) and linalool (LIN) are aromatic compounds that have neuroprotective effects. The main purpose of this study is to evaluate the anxiolytic activity of LIN and SES co-treatment on Swiss albino mice and analyze its possible mechanism through in silico study. In this sense, the mice were given the gamma-aminobutyric acid type A receptors (GABA) agonist diazepam (DZP; 3 mg/kg, p.
View Article and Find Full Text PDFMeasuring Alcohol-Induced Striatal Dopamine Release in Healthy Humans With [C]-Raclopride: A Meta-Analysis.
Synapse
January 2025
Department of Science, De La Salle College, Institute of the Brothers of the Christian Schools, Toronto, Ontario, Canada.
Alcohol consumption is known to affect dopamine (DA) release in the brain, with significant implications for understanding addiction and its neurobiological underpinnings. This meta-analysis examined the effects of acute alcohol administration on striatal DA release in healthy humans as measured with [C]-raclopride positron emission tomography (PET). Oral alcohol administration was associated with a significant reduction in [C]-raclopride binding potential (BP) in the ventral striatum (Cohen's d = -0.
View Article and Find Full Text PDFThe Ability of AST-120 to Lower the Serum Indoxyl Sulfate Level Improves Renal Outcomes and the Lipid Profile in Diabetic and Nondiabetic Animal Models of Chronic Kidney Disease: A Meta-Analysis.
Toxins (Basel)
December 2024
Association pour L'utilisation du rein Artificiel en Région Parisienne (AURA), 75014 Paris, France.
The therapeutic benefit of the oral adsorbent drug AST-120 in chronic kidney disease (CKD) is related to an indoxyl sulfate (IS)-lowering action. Diabetes and dyslipidemia might worsen kidney damage in CKD. However, it is not known whether AST-120 influences lipid abnormalities as well as renal function in patients with CKD and diabetes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!